Ocular Therapeutix Inc
1 day chart
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of therapies for diseases and conditions of the eye. Its first commercial drug product, DEXTENZA, is developed for the treatment of ocular inflammation and pain ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Its earlier stage development assets include: axitinib intravitreal implant (OTX-TKI), is under Phase I clinical trials for the treatment of wet age-related macular degeneration (AMD) and diabetic retinopathy; travoprost intracameral implant (OTX-TIC), is under Phase II clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and dexamethasone intracanalicular insert (OTX-DED), for the short-term treatment of the signs and symptoms of dry eye disease; and cyclosporine intracanalicular insert (OTX-CSI), for the chronic treatment of dry eye disease, both of which have completed Phase II clinical trials.
Buy US stocks in Australia starting with OCUL. Open an account and start investing today!
To do so follow these steps:
- Sign up in minutes, all you need is some I.D.
- Choose Stake Wall St
- Deposit directly into your Stake wallet and you're ready to invest in OCUL
This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.